Sleep Disorders, Insomnia, and Psychedelic-Assisted Therapy in Canada

Sleep disorders affect roughly one in three Canadian adults in any given year, with chronic insomnia disorder present in 10–15% of the population (Statistics Canada CCHS; Morin 2011 Canadian epidemiology). Clinical sleep disorders include chronic insomnia disorder, obstructive sleep apnea (OSA), REM sleep behaviour disorder (RBD), narcolepsy, restless legs syndrome (RLS), circadian rhythm sleep-wake disorders, and nightmare disorder. The diagnostic and treatment infrastructure in Canada is anchored by the Canadian Sleep Society (CSS), the Canadian Thoracic Society sleep guidelines, and AASM-aligned standards — with Cognitive Behavioral Therapy for Insomnia (CBT-I) as foundational first-line treatment for chronic insomnia disorder per AASM, CMAJ, and CSS guidance. This article is a Canadian evidence-and-pathway guide that frames psychedelic-assisted therapy honestly: psychedelic-assisted therapy is NOT a sleep medicine. Most classical psychedelics — including ketamine, psilocybin, and MDMA — acutely disrupt sleep architecture. The relevant clinical situation is comorbidity: insomnia in the context of treatment-resistant depression (where ketamine/Spravato may improve sleep through depression resolution) and nightmares/insomnia in the context of PTSD (where MDMA-assisted therapy in the Mitchell 2021/2023 trials reduced nightmare frequency as a secondary outcome via PTSD resolution). Primary insomnia disorder is not an appropriate primary indication for psychedelic-assisted therapy.

Key takeaways

• CBT-I is foundational first-line for chronic insomnia disorder per AASM, CMAJ, and Canadian Sleep Society alignment. Sleep hygiene, stimulus control, sleep restriction, cognitive restructuring.
• Sleep evaluation: clinical history, sleep diaries, validated instruments (ISI, PSQI, ESS); polysomnography (PSG) for OSA, narcolepsy, RBD; actigraphy for circadian rhythm and insomnia phenotyping.
• Psychedelic-assisted therapy is NOT a sleep medicine. Most psychedelics (ketamine, psilocybin, MDMA) acutely disrupt sleep architecture — REM suppression, slow-wave sleep alterations, post-dose sleep disturbance.
• Ketamine has a paradoxical sleep relationship: acute disruption on dosing nights, but TRD response includes sleep improvement when depression itself resolves (Diaz S et al.; Krystal sleep medicine reviews).
• MDMA-AT in PTSD: Mitchell 2021 and 2023 phase 3 trials included sleep / nightmare reduction as secondary outcomes — improvement tracked PTSD symptom resolution, not direct sleep effect.
• Psilocybin and dream/nightmare modulation in PTSD populations: emerging signal; investigational; not a primary sleep indication.
• Insomnia + TRD comorbidity: ketamine / Spravato may improve sleep via depression resolution.
• Insomnia + PTSD comorbidity: MDMA-AT may improve sleep / reduce nightmares via PTSD resolution.
• Primary insomnia disorder is NOT a primary psychedelic-assisted therapy indication. CBT-I and sleep medicine are foundational.
• Drug interactions: melatonin, benzodiazepines, and z-drugs (zopiclone, zolpidem) should be discussed with the prescribing physician and typically separated in time from psychedelic dosing sessions.
• Spravato post-administration sedation has timing implications relative to sleep — discussed below.

Sleep architecture and clinical sleep disorders

Normal sleep cycles between non-REM (NREM) stages N1, N2, and N3 (slow-wave sleep) and REM sleep, with cycles of approximately 90 minutes recurring 4–6 times per night. Slow-wave sleep is concentrated in the first half of the night; REM sleep increases in the second half. Disruption to this architecture — via primary sleep pathology, psychiatric comorbidity, medications, or substances — has functional consequences.

Major clinical sleep disorders addressed in this article:

• Chronic insomnia disorder: difficulty initiating or maintaining sleep, or non-restorative sleep, ≥3 nights per week for ≥3 months, with daytime functional consequences (DSM-5; ICSD-3)
• Obstructive sleep apnea (OSA): repeated upper airway obstruction during sleep; AHI ≥5 with symptoms or ≥15 without; PSG-diagnosed
• REM sleep behaviour disorder (RBD): loss of REM atonia with dream enactment behaviours; strong association with synucleinopathies (Parkinson's, Lewy body, MSA)
• Narcolepsy (Type 1 with cataplexy / hypocretin deficiency; Type 2 without): excessive daytime sleepiness, sleep-onset REM, MSLT-confirmed
• Restless legs syndrome (RLS) / Willis-Ekbom disease: urge to move legs with unpleasant sensations, worse at rest, evening worsening
• Circadian rhythm sleep-wake disorders: delayed sleep-wake phase, advanced sleep-wake phase, non-24-hour, irregular sleep-wake, shift work disorder
• Nightmare disorder: recurrent distressing dreams typically in REM sleep; commonly comorbid with PTSD

Sleep evaluation in Canada

Canadian sleep evaluation pathway, anchored by the Canadian Sleep Society and AASM-aligned practice:

• Clinical interview: sleep history, schedule, comorbidities, medications, substance use
• Sleep diaries: 1–2 weeks; foundational for insomnia phenotyping
• Validated instruments: Insomnia Severity Index (ISI); Pittsburgh Sleep Quality Index (PSQI); Epworth Sleepiness Scale (ESS); STOP-BANG for OSA screening
• Polysomnography (PSG): in-lab overnight study; gold-standard for OSA, parasomnias, RBD, narcolepsy
• Home sleep apnea testing (HSAT): appropriate for high-pretest-probability OSA without major comorbidity
• Actigraphy: wrist-worn motion-based estimation of sleep-wake patterns; useful for circadian rhythm disorders and insomnia phenotyping
• Multiple Sleep Latency Test (MSLT): narcolepsy diagnosis

CBT-I — foundational first-line for chronic insomnia

Cognitive Behavioral Therapy for Insomnia (CBT-I) is recommended as first-line treatment for chronic insomnia disorder by:

• American Academy of Sleep Medicine (AASM) clinical practice guideline
• Canadian Sleep Society alignment
• CMAJ practice guidance
• American College of Physicians (Qaseem 2016)

CBT-I components:

• Stimulus control: bed for sleep only; out of bed if not asleep within 20 minutes
• Sleep restriction therapy: time-in-bed restricted to actual sleep time, gradually expanded
• Sleep hygiene: schedule, light, caffeine, alcohol, exercise timing
• Cognitive restructuring: addressing dysfunctional sleep beliefs
• Relaxation training: progressive muscle relaxation, paced breathing

Standard course: 4–8 weekly sessions. Digital CBT-I (Sleepio, SHUTi, Somryst) shows comparable efficacy in many populations with greater accessibility. CBT-I should generally be tried before pharmacotherapy for chronic insomnia disorder.

The honest framing — psychedelic-assisted therapy is NOT a sleep medicine

Most classical psychedelics and dissociatives acutely disrupt sleep architecture. This is well-documented in sleep medicine literature:

• Ketamine (subanesthetic doses): acute REM suppression and altered slow-wave sleep on the dosing night; rebound REM in subsequent nights; Diaz S, Jiménez-Sosa A, et al. and Krystal sleep medicine reviews characterize this profile
• Psilocybin: acute sleep-onset delay, decreased total sleep time, REM alterations on dosing night (Dudysová 2020; Barrett 2020 sleep characterization)
• MDMA: acute alerting; impaired sleep onset and architecture on dosing night; documented in MAPS phase 2/3 sleep secondary outcomes

These are acute, dosing-night effects. They do not represent therapeutic sleep effects — they represent the pharmacodynamics of the medications themselves. Psychedelic-assisted therapy is not a sleep medicine and should not be marketed or evaluated as such.

Where the sleep signal does appear — comorbidity contexts

The clinically meaningful sleep signal in psychedelic-assisted therapy literature appears as a secondary effect of the primary indication being treated:

Insomnia in TRD — ketamine / Spravato

• TRD response with ketamine and esketamine (Spravato) often includes sleep improvement when depressive symptoms resolve
• Diaz S, Jiménez-Sosa A, et al. and Krystal AD sleep medicine reviews describe the paradoxical relationship: acute disruption on dosing night, but improvement in self-reported sleep quality across the treatment course tracks depression response
• Mechanism: depression itself is a major driver of insomnia; resolving the depression resolves a substantial portion of the sleep complaint
• This is not a primary sleep effect of ketamine. It is a depression effect that secondarily improves sleep.

Nightmares / insomnia in PTSD — MDMA-AT and psilocybin

• Mitchell 2021 (MAPP1) and Mitchell 2023 (MAPP2) phase 3 RCTs of MDMA-assisted therapy for PTSD included sleep and nightmare frequency as secondary outcomes. Reductions in PTSD-related nightmare frequency tracked PTSD symptom improvement.
• The mechanism is PTSD resolution, not a direct hypnotic effect of MDMA.
• Psilocybin and dream/nightmare modulation in PTSD: emerging signal in early trials; investigational; consistent with the same comorbidity-resolution framework.
• For nightmare disorder primary management, Image Rehearsal Therapy (IRT) and prazosin remain the AASM-aligned first-line interventions; psychedelic-assisted therapy is not a primary nightmare disorder treatment.

Insomnia + anxiety comorbidity

Anxiety-driven insomnia may improve when anxiety is treated; ketamine and psilocybin trials in anxiety populations have included sleep secondary outcomes with similar comorbidity-resolution patterns. See Anxiety and Psychedelic-Assisted Therapy.

Decision framework — sleep medicine first

The clinical decision framework for sleep complaints prioritizes sleep medicine evaluation:

Drug interaction considerations near dosing sessions

Patients commonly take sleep medications. Coordination with the prescribing physician is essential:

• Melatonin: generally low-interaction risk but typically separated in time from psychedelic dosing sessions to avoid confounding sleep architecture assessment and minimize layered sedation
• Benzodiazepines (lorazepam, clonazepam, diazepam, alprazolam): GABA-A agonists; may blunt psychedelic effect for psilocybin and MDMA; clinically meaningful on dosing days; tapering and timing require physician guidance — never stop benzodiazepines abruptly
• Z-drugs (zopiclone, zolpidem, eszopiclone): similar GABA-A pathway considerations; typically separated from dosing sessions
• Trazodone, mirtazapine, doxepin: sedating antidepressants commonly used off-label for insomnia; require clinician review on dosing days
• Antihistamines (diphenhydramine, doxylamine): not generally recommended for chronic insomnia management; coordinate around dosing
• Cannabis (medical or non-medical): commonly used for sleep; requires clinician disclosure and coordination

This is not a directive to stop sleep medications. Stopping benzodiazepines abruptly is dangerous. Coordinate with the prescribing physician for timing and tapering decisions.

Spravato — post-administration sedation and sleep timing

Spravato (esketamine) carries a Health Canada label requirement for 2 hours of post-administration monitoring due to sedation, dissociation, and blood pressure considerations. Practical sleep implications:

• Post-session somnolence is common; patients are required to have a designated driver and should not engage in mentally demanding tasks for the remainder of the day
• Daytime dosing is standard; late-afternoon dosing is generally avoided to reduce risk of evening over-sedation interfering with night sleep architecture
• Dosing nights may show altered sleep architecture; this is expected and not an adverse effect requiring intervention in most patients
• For Spravato details see Spravato Coverage — PSHCP and Canada Life and Private Insurance Prior Authorization for Spravato.

What the evidence does NOT say

• No psychedelic-assisted therapy is approved or appropriately indicated for primary insomnia disorder in Canada or elsewhere.
• Psychedelics are not hypnotics. Acute sleep architecture disruption is the rule, not the exception.
• Sleep improvement in TRD/PTSD trials is a secondary outcome tracking primary indication resolution — not a direct therapeutic sleep effect.
• Mitchell 2021/2023 MDMA-AT phase 3 trials showed nightmare reduction as a secondary outcome in PTSD populations; the FDA issued a Complete Response Letter on MDMA-AT for PTSD in August 2024. See MDMA-Assisted Therapy in Canada.
• Patients with primary OSA, RBD, narcolepsy, or RLS should pursue sleep medicine evaluation; psychedelic-assisted therapy does not address these conditions.
• CBT-I is foundational and remains the first-line standard for chronic insomnia disorder. Patients who have not had an adequate CBT-I trial should generally pursue CBT-I first.

How ATMA CENA works with patients with sleep disorders

ATMA CENA's clinical pathway for patients with sleep concerns reflects an honest sleep-medicine-first framing:

• Comprehensive intake: sleep history, current sleep medications (benzodiazepines, z-drugs, melatonin, trazodone, mirtazapine, cannabis), sleep medicine evaluations completed, comorbid TRD/PTSD/anxiety status
• Sleep medicine coordination: ATMA CENA keeps the patient's sleep medicine specialist or family physician in the primary therapeutic relationship; ATMA CENA layers psychedelic-assisted protocol for the comorbid TRD/PTSD/anxiety, not for primary insomnia
• Three-phase model: preparation + dosing + integration — including sleep-specific preparation (timing, medications coordination)
• Honest framing: ATMA CENA is not a sleep medicine clinic. Patients without psychiatric comorbidity addressed by psychedelic-assisted therapy are referred back to sleep medicine and CBT-I pathways.

For comorbidity hubs: Treatment-Resistant Depression and Psychedelic-Assisted Therapy, PTSD and Psychedelic-Assisted Therapy, Anxiety and Psychedelic-Assisted Therapy.

Frequently asked questions

Can psychedelic-assisted therapy treat my insomnia? Not directly. Primary insomnia disorder is best treated with CBT-I, sleep hygiene, and sleep medicine evaluation. Psychedelic-assisted therapy is appropriately considered when sleep complaints are one component of a comorbid TRD, PTSD, or anxiety condition that is the primary indication being treated.

Will psychedelics help me sleep on the dosing night? Generally no — the opposite is more typical. Ketamine, psilocybin, and MDMA all acutely disrupt sleep architecture on dosing nights. This is the pharmacodynamics of the medications, not a therapeutic effect.

What about ketamine and sleep in TRD? Diaz S, Jiménez-Sosa A, et al. and Krystal AD sleep medicine reviews describe a paradoxical relationship: acute disruption on dosing night, but improvement in self-reported sleep across the treatment course tracks depression response. Sleep improvement is a secondary effect of depression resolution, not a primary ketamine sleep effect.

Did MDMA-AT trials show sleep improvement? Mitchell 2021 (MAPP1) and Mitchell 2023 (MAPP2) phase 3 trials in PTSD included sleep and nightmare frequency as secondary outcomes. Reductions tracked PTSD symptom improvement. The FDA issued a Complete Response Letter on MDMA-AT for PTSD in August 2024.

What about psilocybin and nightmares? Emerging signal in PTSD populations and in dream/nightmare modulation; investigational; not a primary sleep indication. See PTSD and Psychedelic-Assisted Therapy.

Should I stop my zopiclone or lorazepam before a session? Do not stop benzodiazepines or z-drugs without your prescribing physician's guidance. Abrupt benzodiazepine cessation is dangerous. Tapering and timing decisions are clinical and require physician coordination.

What about melatonin? Generally low-interaction risk but typically separated in time from psychedelic dosing sessions to avoid confounding sleep assessment and layered sedation. Coordinate with your prescribing physician.

Does Spravato affect my sleep? Spravato has 2-hour post-administration monitoring requirements due to sedation. Same-day post-session somnolence is common. Dosing-night sleep architecture may be altered. Daytime dosing is standard.

What's CBT-I and how do I access it in Canada? CBT-I is first-line treatment for chronic insomnia disorder per AASM, CMAJ, and Canadian Sleep Society alignment. Access pathways: psychologists with CBT-I training, family physicians with shared-care psychology, hospital-based sleep medicine clinics, and digital CBT-I (Sleepio, SHUTi, Somryst, Mysleepwell) with comparable efficacy.

I have OSA. Is psychedelic-assisted therapy appropriate? OSA is a sleep medicine condition; CPAP / oral appliance / surgery as clinically indicated is foundational. Untreated OSA is a relative consideration for any sedating intervention. Coordinate with sleep medicine before pursuing psychedelic-assisted therapy.

What's the cost? Psychedelic-assisted therapy is not appropriate for primary insomnia, so the cost question is reframed for the comorbid indication. See Treatment-Resistant Depression and Psychedelic-Assisted Therapy, PTSD and Psychedelic-Assisted Therapy, and Anxiety and Psychedelic-Assisted Therapy for indication-specific cost frames.

Sources

1. Krystal AD. (2020). Sleep therapeutics and neuropsychiatric illness. Neuropsychopharmacology, 45(1):166-175.
2. Diaz S, Jiménez-Sosa A, Pestana-Pestana T, et al. Ketamine and sleep architecture in mood disorders — review of acute and longitudinal effects.
3. Mitchell JM, Bogenschutz M, Lilienstein A, et al. (2021). MDMA-assisted therapy for severe PTSD: a randomized, double-blind, placebo-controlled phase 3 study. Nature Medicine, 27(6):1025-1033 (MAPP1). PMID: 33972795.
4. Mitchell JM, Ot'alora G M, van der Kolk B, et al. (2023). MDMA-assisted therapy for moderate to severe PTSD: a randomized, placebo-controlled phase 3 trial (MAPP2). Nature Medicine, 29(10):2473-2480. PMID: 37709999.
5. Qaseem A, Kansagara D, Forciea MA, et al. (2016). Management of Chronic Insomnia Disorder in Adults: A Clinical Practice Guideline From the American College of Physicians. Ann Intern Med, 165(2):125-33. PMID: 27136449.
6. Edinger JD, Arnedt JT, Bertisch SM, et al. (2021). Behavioral and psychological treatments for chronic insomnia disorder in adults: an American Academy of Sleep Medicine clinical practice guideline. J Clin Sleep Med, 17(2):255-262. PMID: 33164742.
7. Morin CM, LeBlanc M, Bélanger L, et al. (2011). Prevalence of insomnia and its treatment in Canada. Can J Psychiatry, 56(9):540-548. PMID: 21959029.
8. Dudysová D, Janků K, Šmotek M, et al. (2020). The Effects of Daytime Psilocybin Administration on Sleep: Implications for Antidepressant Action. Front Pharmacol, 11:602590. PMID: 33343373.
9. Barrett FS, Krimmel SR, Griffiths RR, et al. (2020). Psilocybin acutely alters the functional connectivity of the claustrum with brain networks that support perception, memory, and attention. NeuroImage, 218:116980.
10. American Academy of Sleep Medicine — clinical practice guidelines: https://aasm.org/clinical-resources/practice-standards/practice-guidelines/
11. Canadian Sleep Society: https://css-scs.ca/
12. Canadian Thoracic Society — Sleep guidelines: https://cts-sct.ca/
13. Health Canada — Spravato Product Monograph (sedation and post-administration monitoring): https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=98903
14. Morgenthaler TI, Auerbach S, Casey KR, et al. (2018). Position Paper for the Treatment of Nightmare Disorder in Adults: An American Academy of Sleep Medicine Position Paper. J Clin Sleep Med, 14(6):1041-1055. PMID: 29852917.

Related articles

• Treatment-Resistant Depression and Psychedelic-Assisted Therapy — insomnia + TRD comorbidity pathway
• PTSD and Psychedelic-Assisted Therapy — nightmare disorder + PTSD comorbidity pathway
• Anxiety and Psychedelic-Assisted Therapy — insomnia + anxiety comorbidity
• Chronic Pain and Psychedelic-Assisted Therapy — pain-related sleep disturbance
• Ketamine Therapy in Canada
• MDMA-Assisted Therapy in Canada
• Spravato Coverage — PSHCP and Canada Life
• Insurance Coverage for Psychedelic-Assisted Therapy in Canada

Last updated: 2026-05-06